---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-001488"
form_type: "8-K"
ticker: "AXSM"
cik: "0001579428"
company_name: "Axsome Therapeutics, Inc."
filed_at: "2024-01-04T23:59:59+00:00"
generated_at: "2026-06-07T03:57:16.668903+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Axsome reports preliminary Q4 net product revenue of $71M; full year $204M

## Summary
- Preliminary total net product revenue: $71M for Q4 2023, $204M for full year 2023.
- Auvelity net sales: $49M Q4, $130M FY; Sunosi net revenue: $22M Q4, $74M FY.
- 2024 regulatory milestones: NDA submission for AXS-14 (fibromyalgia) Q1; NDA resubmission for AXS-07 (migraine) H1.
- 2024 clinical readouts: Phase 3 SYMPHONY (narcolepsy) Q1, ADVANCE-2 (Alzheimer's agitation) H1, FOCUS (ADHD) H2.
- 2024 trial initiations: Phase 3 solriamfetol for MDD, BED, SWD Q1; Phase 2/3 AXS-05 for smoking cessation.

## SEC filing metadata
- accession: 0000950170-24-001488
- form_type: 8-K
- ticker: AXSM
- cik: 0001579428
- company_name: Axsome Therapeutics, Inc.
- filed_at: 2024-01-04T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1579428/000095017024001488/0000950170-24-001488-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1579428/000095017024001488/axsm-20240104.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-001488
- JSON: https://secwatch.observer/filing/0000950170-24-001488.json
- Plain text: https://secwatch.observer/filing/0000950170-24-001488.txt

## Key facts
- Earnings Releases
  Axsome Therapeutics, Inc. reported the full year of 2023 results: revenue $204 million.
  - Period: the full year of 2023
  - Revenue: $204 million
  - Result: preliminary results
  source text: Axsome expects total product revenue to be approximately $71 million and $204 million for the fourth quarter and full year of 2023, respectively.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1579428/000095017024001488/0000950170-24-001488-index.htm
- Earnings Releases
  Axsome Therapeutics, Inc. reported the fourth quarter of 2023 results: revenue $71 million.
  - Period: the fourth quarter of 2023
  - Revenue: $71 million
  - Result: preliminary results
  source text: Axsome expects total product revenue to be approximately $71 million and $204 million for the fourth quarter and full year of 2023, respectively.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1579428/000095017024001488/0000950170-24-001488-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.